Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.

ASIAIR > College of Medical and Health Science > Department of Biotechnology > Journal Article > Item 310904400/111963

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/111963

Title:	Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.
Authors:	Lee, PC
Contributors:	生物科技學系
Date:	2018-12
Issue Date:	2019-09-10 05:23:17 (UTC+0)
Abstract:	Multiple mechanisms of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been identified in EGFR-mutant non-small cell lung cancer (NSCLC); however, recurrent resistance to EGFR TKIs due to the heterogeneous mechanisms underlying resistance within a single patient remains a major challenge in the clinic. Here, we report a role of nuclear protein kinase Cδ (PKCδ) as a common axis across multiple known TKI-resistance mechanisms. Specifically, we demonstrate that TKI-inactivated EGFR dimerizes with other membrane receptors implicated in TKI resistance to promote PKCδ nuclear translocation. Moreover, the level of nuclear PKCδ is associated with TKI response in patients. The combined inhibition of PKCδ and EGFR induces marked regression of resistant NSCLC tumors with EGFR mutations.
Relation:	CANCER CELL
Appears in Collections:	[Department of Biotechnology] Journal Article

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	213	View/Open

View Licence